Lazertinib vs Osimertinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Lazertinib

Marketed by Johnson & Johnson and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04248829 · Phase 3 · completed

The trial randomized 393 participants to lazertinib or an active gefitinib control with double-blind treatment. Its primary clinical endpoint, investigator-assessed progression-free survival, was met: median 20.6 vs 9.7 months (HR 0.45, 95% CI 0.34 to 0.58; P < .001; PMID 37379502).

Next expected readout: December 2026 · NCT05463224 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46) (met)

Result source: NCT04487080

Osimertinib · Tagrisso

Marketed by AstraZeneca

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02151981 · Phase 3 · completed

The trial was randomized and actively controlled, with 279 patients receiving osimertinib and 140 receiving platinum-based chemotherapy, but treatment assignment was not blinded. Its primary clinical endpoint, investigator-assessed progression-free survival, favored osimertinib significantly (hazard ratio 0.30; p<0.001), supporting moderate-strength evidence rather than the strongest level because the study was open-label.

Next expected readout: November 2026 · NCT05998993 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6) (met)

Result source: NCT02151981

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLazertinibOsimertinib
PFS, median20.6 vs 9.7vs Gefitnib240 mg · n 196NCT04248829
6 other results
19.5 vs 22.0vs Gefitinibn 45NCT02856893
1 other result
OS, median9.1b240 mg · n 11NCT04075396
1 other result
  • 7.7 320 mg · n 9 · Phase 1/2 · secondary NCT04075396
—Not posted · NCT05015608
ORR76% vs 76.1%vs Gefitnib240 mg · n 196NCT04248829
2 other results
  • 26.7% 240 mg · n 15 · Phase 1/2 · secondary NCT04075396
  • 7.7% 320 mg · n 13 · Phase 1/2 · secondary NCT04075396
76%bn 25NCT02789345
Duration of response, median19.4 vs 8.3vs Gefitnib240 mg · n 196NCT04248829
1 other result
  • 2.8 320 mg · n 1 · Phase 1/2 · secondary NCT04075396
13.4bn 19NCT02789345

PFS, median

Lazertinib
20.6 vs 9.7vs Gefitnib240 mg · n 196NCT04248829
6 other results
Osimertinib
19.5 vs 22.0vs Gefitinibn 45NCT02856893
1 other result

OS, median

Lazertinib
9.1b240 mg · n 11NCT04075396
1 other result
  • 7.7 320 mg · n 9 · Phase 1/2 · secondary NCT04075396
Osimertinib
—Not posted · NCT05015608

ORR

Lazertinib
76% vs 76.1%vs Gefitnib240 mg · n 196NCT04248829
2 other results
  • 26.7% 240 mg · n 15 · Phase 1/2 · secondary NCT04075396
  • 7.7% 320 mg · n 13 · Phase 1/2 · secondary NCT04075396
Osimertinib
76%bn 25NCT02789345

Duration of response, median

Lazertinib
19.4 vs 8.3vs Gefitnib240 mg · n 196NCT04248829
1 other result
  • 2.8 320 mg · n 1 · Phase 1/2 · secondary NCT04075396
Osimertinib
13.4bn 19NCT02789345
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. Lazertinib: 9 of 9 rows · Osimertinib: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLazertinib
Rows use multiple source trials
Osimertinib
Rows use multiple source trials
Disease Control
responder rate · % of participants
No placebo or comparator arm
60% (n=15)240 mga,b,c,d,e
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more dose
53.8% (n=13)320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
92% (n=25)b,c,d,e
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Duration of Response
time to event · months
No placebo or comparator arm
NA months240 mga,b,c,d,e
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more dose
2.8 months320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
13.37 monthsb,c,d,e
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
ORR
responder rate · % of participants
No placebo or comparator arm
26.7% (n=15)240 mga,b,c,d,e
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more dose
7.7% (n=13)320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
76% (n=25)b,c,d,e
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Overall Survival
time to event · months
No placebo or comparator arm
9.1 months240 mga,b,c,d,e
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more dose
7.7 months320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
NA monthsb,c,d,e
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
3.1 months240 mga,b,c,d,e
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more dose
4.2 months320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
11.04 monthsb,c,d,e
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Dropout rate
44.9%240 mgf
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
78.1%Experimental: Arm A (Open-label):
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
75%Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
74.5%Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
80.2%Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—240 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
62.3%g
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
100%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
77.3%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
9.7%240 mgf
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
—Experimental: Arm A (Open-label):
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—240 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
—320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
3.8%g
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
0%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
4.5%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
26%240 mgf
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
48.7%Experimental: Arm A (Open-label):
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
35.2%Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
52.1%Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
32.3%Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
66.7%240 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
46.2%320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
17%g
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
33.3%Arm A: Ramucirumab + Osimertinib
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
36.4%Cohort A: Ramucirumab + Osimertini
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
240 mgf
paraesthesia 39.3%
rash 36.2%
pruritus 26.5%
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
paronychia 68.4%
infusion related reaction 62%
rash 61.8%
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
rash 44.6%
diarrhoea 31.9%
paronychia 28.6%
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
neutropenia 65.8%
thrombocytopenia 59.3%
infusion related reaction 54%
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
infusion related reaction 56.9%
neutropenia 56.2%
nausea 44.6%
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
240 mg
anaemia 46.7%
diarrhoea 46.7%
aspartate aminotransferase increased 26.7%
NCT04075396 · Phase 1/2 · registry result, not featured evidence
320 mg
nausea 61.5%
diarrhoea 53.8%
arthralgia 23.1%
NCT04075396 · Phase 1/2 · registry result, not featured evidence
g
diarrhea 50.9%
dry skin 41.5%
weight loss 35.8%
NCT02856893 · Phase 2 · registry result, not featured evidence
show 2 more results
cough 100%
diarrhoea 100%
arthralgia 66.7%
NCT02789345 · Phase 1 · registry result, not featured evidence · combination
diarrhoea 63.6%
hypertension 63.6%
decreased appetite 40.9%
NCT02789345 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 1 versus Phase 1/2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eThe assessment timepoint is not available for both results.
  6. fPopulation comparability has not been reviewed for 2 of these studies.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lazertinib

ORR 76% (n=196) vs 76.1% (n=197) Gefitnib240 mg
responder rate · % of participants
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Duration of Response 19.4 vs 8.3 Gefitnib months240 mg
time to event · months
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Disease Control 93.9% (n=196) vs 93.9% (n=197) Gefitnib240 mg
responder rate · % of participants
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Overall Survival 25% (n=196) vs 32.5% (n=197) Gefitnib240 mg
event count · % of participants
Death
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 · converted to % from 49 Participants as posted
Tumor Size -5.37% (n=14)240 mg
percent change · % of baseline
No placebo or comparator arm
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more result
9.56% (n=12)320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence

Osimertinib

PFS18 51.1% (n=45) vs 67.2% (n=47) Gefitinib @ 78wk
responder rate · % of participants
NCT02856893 · Phase 2 · registry result, not featured evidence
Time to Progression 19.48 vs 10.81 Gefitinib months
time to event · months
NCT02856893 · Phase 2 · registry result, not featured evidence
ORR 0.889 vs 0.656 Gefitinib count
event count · count
NCT02856893 · Phase 2 · registry result, not featured evidence
Overall Survival NA vs NA Gefitinib months
time to event · months
NCT02856893 · Phase 2 · registry result, not featured evidence
Intracranial PFS 34.3 vs 24.44 Gefitinib months
absolute value · months
NCT02856893 · Phase 2 · registry result, not featured evidence
PFS2 25.76 vs 21.98 Gefitinib months
time to event · months
NCT02856893 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lazertinib's landscape · Osimertinib's landscape